Myriad Genetics Sees 10% Revenue Growth in Q1 2023
The company reaffirms its profitability projection for Q4 2023
Myriad Genetics (NASDAQ:MYGN) produced $181.2 million in revenue for its first quarter, ended 31 March 2023, growth of 10% versus revenue of $164.6 million in the same quarter in 2022.
According to the company news release, revenue for